Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in relapsed/refractory ABC DLBCL
NCT02112526Phase 1Completed
- Sponsor
- Acerta Pharma
- Start
- Aug 2014
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of acalabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Acerta Pharma. Primary endpoint: Safety Profile of Acalabrutinib. Started Aug 2014; status: completed.
02
Drugs
acalabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02112526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02112526.